Literature DB >> 19169162

Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical.

Michael L Power1, Britta L Anderson, Jay Schulkin.   

Abstract

OBJECTIVE: To examine the opinions of obstetrician-gynecologists regarding hormone therapy (HT) and the results from the Women's Health Initiative (WHI).
METHODS: Separate surveys were sent to two groups of practicing obstetrician-gynecologists: (1) respondents to a 2004-2005 survey (follow-up 1) and (2) members of the American College of Obstetricians and Gynecologists' Collaborative Ambulatory Research Network (follow-up 2 CARN). These studies complete a longitudinal study investigating obstetrician-gynecologists' opinions of the evidence from WHI.
RESULTS: Response rates were 64.5% and 58.8%, respectively. Responses from both surveys were generally consistent with the results from the 2004-2005 survey. A majority of physicians from both survey populations were skeptical of the combined HT results. Respondents were more likely to find the results of the unopposed estrogen trial convincing. Similar to the results from the 2004-2005 study, CARN physicians generally disagreed with the decision to end the WHI trials. Unlike the 2004-2005 study, there was no consistent effect of either age or year that residency was completed on physician opinions. Similar to the 2004-2005 study, physicians who considered alternative therapies as viable treatment options were more likely to report that they found the trial results convincing. The results from follow-up 2 CARN indicate that physicians in the south were most likely and physicians in the east were least likely to prescribe HT, suggesting that unmeasured sociocultural parameters might influence HT prescribing practice.
CONCLUSIONS: Obstetrician-gynecologists remain generally skeptical of the WHI results, although less so of the estrogen-only trial. The early end to the trials may have contributed to their skepticism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169162      PMCID: PMC2762611          DOI: 10.1097/gme.0b013e31818fc36e

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  14 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

2.  Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.

Authors:  Sumit R Majumdar; Elizabeth A Almasi; Randall S Stafford
Journal:  JAMA       Date:  2004-10-27       Impact factor: 56.272

3.  Evidence and opinion: closing the gap.

Authors:  Jeffrey L Ecker
Journal:  Menopause       Date:  2007 Jan-Feb       Impact factor: 2.953

4.  A survey of obstetrician-gynecologists concerning practice patterns and attitudes toward hormone therapy.

Authors:  Michael L Power; Stanley Zinberg; Jay Schulkin
Journal:  Menopause       Date:  2006 May-Jun       Impact factor: 2.953

5.  Contemporary clinical issues in outpatient obstetrics and gynecology: findings of the Collaborative Ambulatory Research Network, 2001-2004: part II.

Authors:  Victoria H Coleman; Michael L Power; Stanley Zinberg; Jay Schulkin
Journal:  Obstet Gynecol Surv       Date:  2004-11       Impact factor: 2.347

6.  Contemporary clinical issues in outpatient obstetrics and gynecology: findings of the Collaborative Ambulatory Research Network, 2001-2004: part I.

Authors:  Victoria H Coleman; Michael L Power; Stanley Zinberg; Jay Schulkin
Journal:  Obstet Gynecol Surv       Date:  2004-11       Impact factor: 2.347

7.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

8.  Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy.

Authors:  Bruce Ettinger; Deborah Grady; Anna N A Tosteson; Alice Pressman; Judith L Macer
Journal:  Obstet Gynecol       Date:  2003-12       Impact factor: 7.661

9.  Impact of the women's health initiative trial results on hormone replacement therapy.

Authors:  Megan B Bestul; Marianne McCollum; Laura B Hansen; Joseph J Saseen
Journal:  Pharmacotherapy       Date:  2004-04       Impact factor: 4.705

10.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

View more
  8 in total

1.  Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative.

Authors:  Susan L Lakey; Susan D Reed; Andrea Z LaCroix; Lou Grothaus; Katherine M Newton
Journal:  J Womens Health (Larchmt)       Date:  2010-11-09       Impact factor: 2.681

2.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Authors:  Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan L Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice
Journal:  JAMA       Date:  2010-10-20       Impact factor: 56.272

3.  The haunting of medical journals: how ghostwriting sold "HRT".

Authors:  Adriane J Fugh-Berman
Journal:  PLoS Med       Date:  2010-09-07       Impact factor: 11.069

4.  Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk.

Authors:  Leslie Bernstein
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

5.  Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles.

Authors:  Adriane Fugh-Berman; Christina Pike McDonald; Alicia M Bell; Emily Catherine Bethards; Anthony R Scialli
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

Review 6.  Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis.

Authors:  MinFang Tao; YinCheng Teng; HongFang Shao; Ping Wu; Edward J Mills
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

7.  Attitudes and practices of gynecologists in Jaipur toward management of menopause.

Authors:  Shuchita Meherishi; Sunila Khandelwal; M L Swarankar; Prabhleen Kaur
Journal:  J Midlife Health       Date:  2010-07

8.  Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage.

Authors:  Fiona Chew; Xianwei Wu
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.